Humacyte, Inc. (HUMA)
About Humacyte, Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.0M
- Net income
- -$40.8M
- Total assets
- $116.4M
- Market cap
- $299.7M
- Gross margin
- -376.1%
- Operating margin
- -5306.0%
- Net margin
- -2003.6%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.0M
- Cost of revenue
- $9.7M
- Gross profit
- -$7.7M
- Operating expenses
- $100.5M
- Operating income
- -$108.1M
- Income tax
- $0
- Net income
- -$40.8M
- EPS (basic)
- $-0.26
- EPS (diluted)
- $-0.26
Balance sheet
- Total assets
- $116.4M
- Current assets
- $67.8M
- Total liabilities
- $113.3M
- Current liabilities
- $18.4M
- Shareholders’ equity
- $3.1M
Cash flow
- Operating cash flow
- -$105.0M
- Investing cash flow
- -$884.0K
- Financing cash flow
- $61.5M
- Net cash flow
- -$44.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $299.7M
- EPS (diluted)
- $-0.26
- Shares outstanding
- 483.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 27, 2021
Humacyte, Inc. (HUMA) Stock Price
- Reported a net loss of $40.8M in FY2025.
- Revenue grew 61% from FY2021 to FY2025.
- Gross margin of -376.1%, net margin -2003.6%.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Humacyte, Inc..
Write a review
News about Humacyte, Inc.
News & sentiment via Polygon.io
Humacyte, Inc.: frequently asked questions
Is Humacyte, Inc. an American company?
Humacyte, Inc. is a US-based company headquartered in Durham, North Carolina, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Humacyte, Inc. headquartered?
Humacyte, Inc. is headquartered in Durham, North Carolina, United States.
Is Humacyte, Inc. publicly traded?
Yes — Humacyte, Inc. is a publicly traded company. Its stock trades under the ticker symbol HUMA on the NASDAQ.
What does Humacyte, Inc. do?
Humacyte, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
